

**Supplementary Figure S2.** Immunoblot analysis for MOLM-13 FLT3-ITD cell line treated for 1 hour with 1  $\mu$ M of ARQ 531 multi-kinase inhibitor, ibrutinib irreversible BTK inhibitor, and entospletinib SYK inhibitor **(A)**. 72 hours MTS proliferation assay using MOLM-13 cell line treated with 1  $\mu$ M of ARQ 531, ibrutinib (1 hour washout), or entospletinib **(B)**.

